🔗 Share this article The Global Health Body Issues Concern Over Acute Lack of Obesity Injections Less than a tenth of patients that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it releases its initial advice on the drugs. Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are key obstacles to broad availability to the injections that can help people shift substantial weight, explains the organization. Weight-Loss Drug Supply Crisis Despite the current most favorable scenario, the supply of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the WHO. The advice encourages nations and manufacturers to widen access, through strategies such as licensing agreements. Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in several countries in 2026. How Obesity Jabs Operate The injections imitate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so users reduce food intake. People typically see weight reduction in the initial weeks of commencing the weekly injections. Studies indicates patients may put most of the weight back on after a year of stopping the treatment, as their typical food cravings resume. Being overweight or obese increases your risk for developing medical conditions, like diabetes, heart disease, stroke, and specific malignancies. Excess weight affects individuals in every country and was associated with millions of deaths worldwide in 2024, according to the WHO.
Less than a tenth of patients that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it releases its initial advice on the drugs. Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are key obstacles to broad availability to the injections that can help people shift substantial weight, explains the organization. Weight-Loss Drug Supply Crisis Despite the current most favorable scenario, the supply of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the WHO. The advice encourages nations and manufacturers to widen access, through strategies such as licensing agreements. Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in several countries in 2026. How Obesity Jabs Operate The injections imitate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so users reduce food intake. People typically see weight reduction in the initial weeks of commencing the weekly injections. Studies indicates patients may put most of the weight back on after a year of stopping the treatment, as their typical food cravings resume. Being overweight or obese increases your risk for developing medical conditions, like diabetes, heart disease, stroke, and specific malignancies. Excess weight affects individuals in every country and was associated with millions of deaths worldwide in 2024, according to the WHO.